Difference between revisions of "Therapeutic equivalents"
Jump to navigation
Jump to search
(Created page with "'''This page is very much under construction at the moment.''' =Introduction= Generally speaking, prospective clinical trials are very specific in the drugs that they use in t...") |
m (→Same class) |
||
| Line 21: | Line 21: | ||
[[Category:Stub]] | [[Category:Stub]] | ||
| − | [[Category:General | + | [[Category:Clinical pharmacology]] |
| + | [[Category:General reference pages]] | ||
[[Category:Ontology pages]] | [[Category:Ontology pages]] | ||
Revision as of 12:32, 24 October 2022
This page is very much under construction at the moment.
Introduction
Generally speaking, prospective clinical trials are very specific in the drugs that they use in their evaluation. In clinical practice, one drug is often substituted for another, using the clinical concept of therapeutic equivalence. The purpose of this page is to gather various categories of therapeutic equivalence for general reference, and also to inform the HemOnc ontology. Please keep checking back as the page develops!
Categories of therapeutically equivalent drugs
Biosimilars
Same drug, different route
(e.g., IV and SC daratumumab)
Combinations of agents
(e.g., Phesgo is combined pertuzumab & trastuzumab)
Enantiomers and racemic mixtures
Pro-drugs
(e.g., capecitabine & 5-FU, although this is tricky because of LCV...)
Same class
(e.g., cisplatin and carboplatin)